anti-hiv immune serum globulin (human)
Biologicalexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00000827)
Timeline
Indications
Studied for
Mechanism of action
- Human immunodeficiency virus type I enhancer-binding protein 1Immunity, passive
HIVEP1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-hiv immune serum globulin (human)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000751 | Phase 3 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT00000827 | Phase 1 | Nov 2, 1999 | Nabi Biopharmaceuticals, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000961 | Phase 2 | Nov 2, 1999 | Abbott, Glaxo Wellcome, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00002036 | Phase 1 | Nov 2, 1999 | Abbott |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 2 | 3 | 1999 |
| Abbott | For profit | 2 | 1 | 2 | 1999 |
| Glaxo Wellcome | For profit | 1 | 0 | 1 | 1999 |
| Nabi Biopharmaceuticals | For profit | 1 | 0 | 1 | 1999 |
| National Institutes of Health (NIH) | Government | 1 | 1 | 1 | 1999 |
5 organizations
Page 1 / 1